131.99 -4.19 (-3.08%)
Pre-Market: 9:06AM EDT
|Bid||136.10 x 1100|
|Ask||137.11 x 900|
|Day's Range||135.65 - 137.49|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||22.62|
|Earnings Date||Oct 15, 2019|
|Forward Dividend & Yield||3.80 (2.81%)|
|1y Target Est||150.19|
Shares of Johnson & Johnson swung to a 2.6% decline in premarket trading Friday, after the consumer products and drug company said it was recalling "a single lot" of Johnson's Baby Powder after tests revealed traces of chrysotile asbestos. The stock was trading up about 0.2% ahead of the recall announcement. The company said it initiated the voluntary recall "out of an abundance of caution" after the Food and Drug Administration found "sub-trace" levels of asbestos in samples from a single bottle purchased from an online retailer, and has initiated a "rigorous and thorough" investigation into the matter. J&J said it can't confirm whether the tested product is authentic or counterfeit, or whether the sample was prepared in a controlled environment. The recall comes after J&J received subpoenas earlier this year seeking documents related to the safety of its baby power and other talc-containing products, following at least 13,000 lawsuits claiming the products caused cancer. On Thursday, the company said said rigorous tests of its talc have found not asbestos. The stock has gained 5.5% year to date through Thursday, while the Dow Jones Industrial Average has gained 15.9%.
NEW BRUNSWICK, N.J., Oct. 18, 2019 /PRNewswire/ -- Out of an abundance of caution, Johnson & Johnson Consumer Inc. (JJCI) announced that it is initiating a voluntary recall in the United States of a single lot of its Johnson's Baby Powder in response to a U.S. Food and Drug Administration (FDA) test indicating the presence of sub-trace levels of chrysotile asbestos contamination (no greater than 0.00002%) in samples from a single bottle purchased from an online retailer. In parallel, JJCI has immediately initiated a rigorous, thorough investigation into this matter, and is working with the FDA to determine the integrity of the tested sample, and the validity of the test results.
Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body said on Friday. The treatment, Spravato, which is the chemical mirror image of the often-abused anesthetic ketamine, won U.S. approval in March, making it the first new type of drug for depression in more than 30 years. J&J has said that over 2,000 centers in the U.S. have been certified to administer Spravato, which has been touted as an asset with blockbuster potential.
The chief executives of the three largest U.S. drug distributors and a drugmaker have been summoned to appear before a federal judge to discuss a proposal to resolve thousands of lawsuits alleging they fueled the U.S. opioid crisis, a person familiar with the matter said on Thursday. The order by U.S. District Judge Dan Polster in Cleveland, Ohio, came as distributors McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp and Israel-based drugmaker Teva Pharmaceutical Industries Ltd moved to reach a deal ahead of a trial before Polster that begins on Monday. All of those companies except J&J are set to be defendants in the trial before Polster, who oversees the bulk of the litigation.
The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.
Health care stocks, one of the worst performing sectors, could be poised to outperform even as election turmoil heats up next year. Now, better-than-expected earnings from both UnitedHealth Group Inc. (UNH) and Johnson & Johnson (JNJ) have highlighted health care companies' strong earnings amid a dim overall corporate profit outlook. Health care companies have strong underlying businesses, a factor becoming more attractive in the market as investors shift away from “riskier” assets and more expensive, loss-making companies. And from a valuation perspective, the weakness in the health care space has led many investors to buy health care stocks, which are selling at discounted prices.
Johnson & Johnson has agreed to pay nearly $117 million to resolve allegations that it deceptively marketed transvaginal surgical mesh devices, U.S. state attorneys general said on Thursday. The settlement resolves a multistate investigation that found J&J violated consumer protection laws by misrepresenting the safety and effectiveness of its devices and failing to sufficiently disclose risks associated with their use, the attorneys general said. Thousands of women have sued the company and its Ethicon unit alleging that they were injured by its pelvic mesh devices, which are used to treat bladder issues and pelvic organ prolapse, in which organs shift from their normal positions.
The settlement resolves a multistate investigation that found J&J violated consumer protection laws by misrepresenting the safety and effectiveness of its devices and failing to sufficiently disclose risks associated with their use, the attorneys general said. Thousands of women have sued the company and its Ethicon unit alleging that they were injured by its pelvic mesh devices, which are used to treat bladder issues and pelvic organ prolapse, in which organs shift from their normal positions. The deal does not cover lawsuits over J&J's mesh marketing by four states, California, West Virginia, Kentucky and Mississippi, which remain pending.
NEW BRUNSWICK, N.J., Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on December 10, 2019 to shareholders of record at the close of business on November 26, 2019. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
Shares of Teva Pharmaceutical Industries were up nearly 3% in premarket trading on Thursday amid news that the company has a deal to settle many of the opioid cases against it.
DOW UPDATE Shares of Johnson & Johnson and JPMorgan Chase are seeing strong returns Thursday morning, sending the Dow Jones Industrial Average into positive territory. The Dow (DJIA) is trading 69 points, or 0.
Chinese Aircraft Carrier Factory Revealed This will probably annoy the Trump Administration. Reuters reports exclusively that high-resolution satellite images show that China is progressing in the construction of a full sized aircraft carrier and should be the first of several large vessels produced. The site is called the Jinagnan shipyard and the images were taken […]The post Market Morning: Chinese Aircraft Carriers, DUP Sours on Brexit Deal, Big Opioid Settlement appeared first on Market Exclusive.
Efforts to settle thousands of lawsuits related to the nation’s opioid epidemic intensified Wednesday ahead of the scheduled start of arguments in the first federal trial over the crisis.
Johnson & Johnson (JNJ) generates income from three key segments, including pharmaceuticals, medical devices, and consumer products.
On Wednesday's PreMarket Prep show, earnings reports and ratings changes took a backseat to the negative news for cloud stocks and the positive news for opioid-associated drug distributors. Stormy Outlook ...
On Wednesday morning, Benzinga Pro subscribers were alerted to several unusually large Johnson & Johnson option trades. At 9:47 a.m., a trader sold 850 J&J call options with a $135 strike price expiring on Friday at the bid price of $1.601. At 11:31 a.m., a trader sold 900 J&J $135 call options expiring on Nov. 15 at the bid price of $3.451.
Morgan Stanley’s David Lewis maintained an Equal-weight rating on the stock with a $145 price target. Company officials acknowledged on the Tuesday earnings call that it faces pressure from a number of lawsuits, with CFO Joseph Wolk saying the company is a target for litigation because of its prominence.
Stocks faded back near session lows amid weak retail data and a software drubbing. The Dow Jones industrials held up best as Johnson & Johnson rallied.
Johnson & Johnson has had a $110 million verdict reversed and vacated by a Missouri appellate court in a case claiming that the company's talcum powder caused cancer.
Democratic candidates like Kamala Harris and Amy Klobuchar criticized big pharma companies for their role in the opioid crisis.
Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with ...